These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33497941)

  • 21. Effects of tyrosine kinase inhibitors for controlling Ph+ clone and additional clonal abnormalities in a chronic myeloid leukemia.
    Ganguly BB; Mandal S; Banerjee D; Kadam NN
    J Cancer Res Ther; 2022; 18(3):760-764. PubMed ID: 35900551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
    Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
    Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.
    Wang W; Tang G; Cortes JE; Liu H; Ai D; Yin CC; Li S; Khoury JD; Bueso-Ramos C; Medeiros LJ; Hu S
    J Hematol Oncol; 2015 Apr; 8():32. PubMed ID: 25888368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
    O'Dwyer ME; Mauro MJ; Kurilik G; Mori M; Balleisen S; Olson S; Magenis E; Capdeville R; Druker BJ
    Blood; 2002 Sep; 100(5):1628-33. PubMed ID: 12176881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chronic myeloid leukemia. Karyotype changes].
    Rojas-Atencio A; Pineda-Del Villar L; Avila-León E; González-Ferrer S; Prieto-Carrasquero M; Soto M; González R
    Invest Clin; 1996 Sep; 37(3):167-75. PubMed ID: 8983354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
    Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Giannini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M;
    Cancer Genet Cytogenet; 2010 Jun; 199(2):76-80. PubMed ID: 20471509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools: implication of 1q12-21.
    Su XY; Wong N; Cao Q; Yu LZ; Niu C; Wickham N; Johnson PJ; Chen Z; Chen SJ
    Cancer Genet Cytogenet; 1999 Jan; 108(1):6-12. PubMed ID: 9973917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel BCR-ABL transcript e2a2 in a chronic myelogenous leukaemia patient with a duplicated Ph-chromosome and monosomy 7.
    Leibundgut EO; Jotterand M; Rigamonti V; Parlier V; Mühlematter D; Tobler A; Solenthaler M
    Br J Haematol; 1999 Sep; 106(4):1041-4. PubMed ID: 10520010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
    Terre C; Eclache V; Rousselot P; Imbert M; Charrin C; Gervais C; Mozziconacci MJ; Maarek O; Mossafa H; Auger N; Dastugue N; Talmant P; Van den Akker J; Leonard C; N'Guyen Khac F; Mugneret F; Viguié F; Lafage-Pochitaloff M; Bastie JN; Roux GL; Nicolini F; Maloisel F; Vey N; Laurent G; Recher C; Vigier M; Yacouben Y; Giraudier S; Vernant JP; Salles B; Roussi J; Castaigne S; Leymarie V; Flandrin G; Lessard M;
    Leukemia; 2004 Aug; 18(8):1340-6. PubMed ID: 15190256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.
    Fayad L; Kantarjian H; O'Brien S; Seong D; Albitar M; Keating M; Talpaz M
    Leukemia; 1997 May; 11(5):767-71. PubMed ID: 9180306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
    Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
    Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myeloid leukemia in 2007.
    Sessions J
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S4-9. PubMed ID: 18056931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The influence of additive clonal chromosome abnormalities in Ph negative cells on the efficacy of chronic myeloid leukemia].
    Zhao HF; Zhang Y; Zu YL; Li Z; Zhou J; Yu FK; Hu JY; Wei XD; Song YP
    Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):803-807. PubMed ID: 31665854
    [No Abstract]   [Full Text] [Related]  

  • 38. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
    Lin Y; Bruyère H; Horsman DE; Pantzar T; Barnett MJ; Hogge DE; Nevill TJ; Nantel SH; Sutherland HJ; Toze CL; Shepherd JD; Lavoie JC; Song KW; Smith CA; Forrest DL
    Cancer Genet Cytogenet; 2006 Oct; 170(1):16-23. PubMed ID: 16965950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].
    Yuan T; Wang XY; Lai YY; Qin YZ; Shi HX; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):547-553. PubMed ID: 32397016
    [No Abstract]   [Full Text] [Related]  

  • 40. Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment.
    Gniot M; Lewandowski K; Ratajczak B; Lewandowska M; Lehmann-Kopydłowska A; Jarmuż-Szymczak M; Komarnicki M
    Cancer Genet; 2014; 207(10-12):503-10. PubMed ID: 25496750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.